IL1B and type 2 diabetes mellitus: For example, inhibition of the inflammasome directly led to the suppression of inflammation in adipose tissues and improved insulin-sensitivity in obese patients with type 2 diabetes [5], and blockade of interleukin-1β (IL-1β) resulted in a reduction in gout symptoms [6], suggesting that modulation of inflammasomes could be a promising strategy for the treatment of various inflammatory diseases.